PH12020552048A1 - Methods of treating and preventing alloantibody driven chronic graft versus host disease - Google Patents

Methods of treating and preventing alloantibody driven chronic graft versus host disease

Info

Publication number: PH12020552048A1
Authority: PH; Philippines
Prior art keywords: treating; host disease; methods; versus host; graft versus
Prior art date: 2013-12-02

Application number

PH1/2020/552048A

Other languages

English (en)

Inventor

Bruce R Blazar

Ryan Flynn

Original Assignee

Pharmacyclics Llc

Univ Minnesota

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-02

Filing date

2014-12-02

Publication date

2022-05-11

2014-12-02 Application filed by Pharmacyclics Llc, Univ Minnesota filed Critical Pharmacyclics Llc

2022-05-11 Publication of PH12020552048A1 publication Critical patent/PH12020552048A1/en

Links

208000017760 chronic graft versus host disease Diseases 0.000 title abstract 3
208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 1
208000024908 graft versus host disease Diseases 0.000 abstract 1
XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
229960001507 ibrutinib Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)

PH1/2020/552048A 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease PH12020552048A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361910944P	2013-12-02	2013-12-02
US201461973178P	2014-03-31	2014-03-31
PCT/US2014/068177 WO2015084857A1 (en)	2013-12-02	2014-12-02	Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (1)

Publication Number	Publication Date
PH12020552048A1 true PH12020552048A1 (en)	2022-05-11

Family

ID=53270044

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PH1/2020/552048A PH12020552048A1 (en)	2013-12-02	2014-12-02	Methods of treating and preventing alloantibody driven chronic graft versus host disease
PH12016501051A PH12016501051A1 (en)	2013-12-02	2016-06-02	Methods of treasting and preventing alloantibody driven chronic graft versus host disease

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PH12016501051A PH12016501051A1 (en)	2013-12-02	2016-06-02	Methods of treasting and preventing alloantibody driven chronic graft versus host disease

Country Status (14)

Country	Link
US (6)	US20150157634A1 (2)
EP (1)	EP3076975A4 (2)
JP (5)	JP2017501140A (2)
KR (2)	KR20230104754A9 (2)
CN (2)	CN105939717B (2)
AU (4)	AU2014360758B2 (2)
BR (1)	BR112016012158A2 (2)
CA (2)	CA3210338A1 (2)
EA (1)	EA201691020A1 (2)
IL (4)	IL315228A (2)
MX (2)	MX389020B (2)
PH (2)	PH12020552048A1 (2)
TW (3)	TW202228700A (2)
WO (1)	WO2015084857A1 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA37711A1 (fr)	2012-06-04	2017-05-31	Pharmacyclics Inc	Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CA3103411A1 (en)	2013-10-25	2015-04-30	Pharmacyclics Llc	Use of ibrutinib for treating and preventing chronic graft versus host disease
AR102871A1 (es)	2014-12-03	2017-03-29	Pharmacyclics Llc	Métodos de tratamiento de fibrosis
EP3868374A3 (en)	2016-03-22	2021-11-10	Mayo Foundation for Medical Education and Research	Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) *	2016-06-30	2018-01-04	Sun Pharma Advanced Research Company Limited	Novel hydrazide containing compounds as btk inhibitors
US20200054721A1 (en) *	2016-10-21	2020-02-20	Bruce R. Blazar	Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs)	2017-12-08	2019-06-19	Zentiva, K.S.	Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en)	2019-08-31	2021-03-04	Sun Pharma Advanced Research Company Limited	Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en)	2020-10-19	2025-12-16	Washington University	Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20240025990A1 (en) *	2020-12-01	2024-01-25	City Of Hope	Prevention and treatment of graft-versus-host disease (gvhd)
CN116782946A (zh) *	2021-01-30	2023-09-19	百济神州有限公司	使用btk抑制剂治疗慢性活动性抗体介导的排斥的方法
US12624539B2 (en)	2023-02-28	2026-05-12	Toto Ltd.	Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326469B1 (en)	1994-04-22	2001-12-04	Sugen, Inc.	Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) *	2005-01-25	2006-08-17	Spellberg Brad J	Methods for treating refractory infections in neutropenic individuals
KR20080098490A (ko) *	2006-01-13	2008-11-10	파마시클릭스, 인코포레이티드	티로신 키나제 억제제 및 이의 용도
EP2529621B1 (en) *	2006-09-22	2016-10-05	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
CN102159214A (zh) *	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US8765754B2 (en) *	2009-04-29	2014-07-01	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
EP2473523A2 (en) *	2009-08-31	2012-07-11	Amplimmune, Inc.	Methods and compositions for the inhibition of transplant rejection
MX380504B (es) *	2010-06-03	2025-03-12	Pharmacyclics Llc	El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) *	2010-06-03	2012-03-22	Pharmacyclics, Inc.	Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
ES2548414T3 (es) *	2011-07-08	2015-10-16	Novartis Ag	Novedosos derivados de pirrolo pirimidina
HK1206624A1 (en) *	2012-04-11	2016-01-15	Acerta Pharma B.V.	Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US10722577B2 (en) *	2012-05-25	2020-07-28	Sloan Kettering Institute For Cancer Research	Methods for treating GI syndrome and graft versus host disease
CN104994875B (zh) *	2013-02-15	2018-10-09	免疫医疗公司	嵌合和人源化抗组蛋白抗体
CA3103411A1 (en) *	2013-10-25	2015-04-30	Pharmacyclics Llc	Use of ibrutinib for treating and preventing chronic graft versus host disease
IL315294A (en) *	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of proton tyrosine kinase inhibitor

2014
- 2014-12-02 TW TW110135203A patent/TW202228700A/zh unknown
- 2014-12-02 IL IL315228A patent/IL315228A/en unknown
- 2014-12-02 CA CA3210338A patent/CA3210338A1/en active Pending
- 2014-12-02 JP JP2016536248A patent/JP2017501140A/ja not_active Ceased
- 2014-12-02 US US14/558,297 patent/US20150157634A1/en not_active Abandoned
- 2014-12-02 TW TW112113060A patent/TW202402295A/zh unknown
- 2014-12-02 PH PH1/2020/552048A patent/PH12020552048A1/en unknown
- 2014-12-02 EP EP14867905.3A patent/EP3076975A4/en not_active Withdrawn
- 2014-12-02 WO PCT/US2014/068177 patent/WO2015084857A1/en not_active Ceased
- 2014-12-02 MX MX2016006955A patent/MX389020B/es unknown
- 2014-12-02 KR KR1020237021643A patent/KR20230104754A9/ko active Pending
- 2014-12-02 AU AU2014360758A patent/AU2014360758B2/en active Active
- 2014-12-02 BR BR112016012158A patent/BR112016012158A2/pt not_active Application Discontinuation
- 2014-12-02 KR KR1020167015178A patent/KR20160085817A/ko not_active Abandoned
- 2014-12-02 TW TW103141826A patent/TWI743019B/zh not_active IP Right Cessation
- 2014-12-02 CN CN201480074674.4A patent/CN105939717B/zh active Active
- 2014-12-02 CN CN201910760757.3A patent/CN110478353B/zh active Active
- 2014-12-02 CA CA2932255A patent/CA2932255C/en active Active
- 2014-12-02 EA EA201691020A patent/EA201691020A1/ru unknown
- 2014-12-02 IL IL292522A patent/IL292522A/en unknown
2016
- 2016-05-18 IL IL245715A patent/IL245715A0/en unknown
- 2016-05-27 MX MX2022000209A patent/MX2022000209A/es unknown
- 2016-06-02 PH PH12016501051A patent/PH12016501051A1/en unknown
2017
- 2017-12-01 US US15/829,087 patent/US20180078558A1/en not_active Abandoned
2020
- 2020-02-18 JP JP2020025682A patent/JP2020105181A/ja not_active Ceased
- 2020-06-26 AU AU2020204276A patent/AU2020204276A1/en not_active Abandoned
- 2020-07-29 US US16/942,151 patent/US20210177854A1/en not_active Abandoned
- 2020-08-12 IL IL276683A patent/IL276683A/en unknown
2022
- 2022-04-29 US US17/733,419 patent/US20230100137A1/en not_active Abandoned
- 2022-06-02 AU AU2022203810A patent/AU2022203810B2/en not_active Expired - Fee Related
- 2022-11-25 JP JP2022188655A patent/JP2023029899A/ja not_active Ceased
2023
- 2023-09-25 US US18/372,495 patent/US20240293409A1/en not_active Abandoned
2024
- 2024-01-26 JP JP2024010504A patent/JP2024072291A/ja not_active Ceased
- 2024-12-17 AU AU2024278490A patent/AU2024278490A1/en active Pending
2025
- 2025-01-16 US US19/024,203 patent/US20250381188A1/en active Pending
- 2025-03-27 JP JP2025054634A patent/JP2025118595A/ja active Pending

Also Published As

Publication number	Publication date
CA2932255A1 (en)	2015-06-11
US20230100137A1 (en)	2023-03-30
KR20230104754A (ko)	2023-07-10
US20210177854A1 (en)	2021-06-17
CA2932255C (en)	2023-10-10
AU2014360758B2 (en)	2020-03-26
CN105939717A (zh)	2016-09-14
WO2015084857A1 (en)	2015-06-11
IL245715A0 (en)	2016-07-31
IL315228A (en)	2024-10-01
KR20230104754A9 (ko)	2024-11-15
CN110478353A (zh)	2019-11-22
JP2024072291A (ja)	2024-05-27
AU2020204276A1 (en)	2020-07-16
JP2020105181A (ja)	2020-07-09
TWI743019B (zh)	2021-10-21
AU2014360758A1 (en)	2016-06-16
JP2023029899A (ja)	2023-03-07
PH12016501051A1 (en)	2016-08-15
JP2017501140A (ja)	2017-01-12
US20180078558A1 (en)	2018-03-22
MX389020B (es)	2025-03-20
MX2022000209A (es)	2022-02-03
CA3210338A1 (en)	2015-06-11
EP3076975A1 (en)	2016-10-12
EP3076975A4 (en)	2017-05-03
US20250381188A1 (en)	2025-12-18
CN105939717B (zh)	2019-09-13
EA201691020A1 (ru)	2017-01-30
US20240293409A1 (en)	2024-09-05
AU2022203810B2 (en)	2024-10-03
AU2024278490A1 (en)	2025-01-09
TW201605454A (zh)	2016-02-16
TW202228700A (zh)	2022-08-01
US20150157634A1 (en)	2015-06-11
MX2016006955A (es)	2016-09-07
KR20160085817A (ko)	2016-07-18
AU2022203810A1 (en)	2022-06-23
TW202402295A (zh)	2024-01-16
BR112016012158A2 (pt)	2017-09-26
IL276683A (en)	2020-09-30
JP2025118595A (ja)	2025-08-13
CN110478353B (zh)	2022-12-30
IL292522A (en)	2022-06-01

Publication	Publication Date	Title
ZA202208792B (en)	2023-12-20	Methods of treating and preventing graft versus host disease
PH12016501051A1 (en)	2016-08-15	Methods of treasting and preventing alloantibody driven chronic graft versus host disease
MX2017003933A (es)	2017-06-30	Metodos de tratamiento de la enfermedad hepatica.
MX370573B (es)	2019-12-17	Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
CL2015003731A1 (es)	2016-07-29	Inhibidores de bromodominios
HK1220980A1 (zh)	2017-05-19	用於治疗庞贝氏症的方法和组合物
MX366130B (es)	2019-06-28	Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
PH12016500511A1 (en)	2016-06-13	Selective grp94 inhibitors and uses thereof
UA118248C2 (uk)	2018-12-26	Інгібітори глюкозилцерамідсинтази
TN2015000353A1 (en)	2017-01-03	Newcastle disease viruses and uses thereof
MX2015009058A (es)	2016-01-08	Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PH12014501844A1 (en)	2014-11-17	Peptidomimetic macrocycles
MX2021015735A (es)	2022-06-09	Composiciones de nucleasa terapeuticas y metodos.
AU2012229123A8 (en)	2013-11-07	Methods of treating breast cancer with anthracycline therapy
PT2945642T (pt)	2024-05-27	Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
CA144779S (en)	2012-10-24	Device for performing soft tissue massage
MX2014004074A (es)	2014-06-05	Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX359181B (es)	2018-09-17	Hidrolizado de colágeno y uso del mismo.
IN2014DN08385A (2)	2015-05-08
EP3747907A3 (en)	2021-02-24	Methods and compositions for treating and preventing disease associated with avb8 integrin
EA201690445A1 (ru)	2016-06-30	Лечение рака
MX369455B (es)	2019-11-08	Métodos mejorados para tratamiento de grano con ozono.
HK1228259A1 (en)	2017-11-03	Methods of treating and preventing graft versus host disease
IN2014DN00168A (2)	2015-05-22
BR112013032188A2 (pt)	2016-12-20	composição, produto e método para tratar pacientes com hepatite c crônica